Dosage forms of Tyk2 inhibitor comprising swellable core

The present invention relates to a swellable core dosage form comprising a dispersion of an amorphous 6-(cyclopropanecarboxamide)-4-((2-methoxy-3-(1-methyl-1H-1, 2, 4-triazol-3-yl) phenyl) amino)-N-(methyl-d3) pyridazine-3-carboxamide. 可溶胀核芯剂型包含无定形6-(环丙烷酰胺基)-4-((2-甲氧基-3-(1-甲基-1H-1,2,4-三唑-3-基)苯基)氨基)-...

Full description

Saved in:
Bibliographic Details
Main Authors COLE-KING DAVID, SATHER CLIFFORD A, KOSTUR ULRIKE, BADAWY SHERIF IBRAHIM FARNAZ, KABERTZ KEVIN
Format Patent
LanguageChinese
English
Published 21.07.2023
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to a swellable core dosage form comprising a dispersion of an amorphous 6-(cyclopropanecarboxamide)-4-((2-methoxy-3-(1-methyl-1H-1, 2, 4-triazol-3-yl) phenyl) amino)-N-(methyl-d3) pyridazine-3-carboxamide. 可溶胀核芯剂型包含无定形6-(环丙烷酰胺基)-4-((2-甲氧基-3-(1-甲基-1H-1,2,4-三唑-3-基)苯基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺的分散体。
Bibliography:Application Number: CN202180074961